Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

I will probably miss out on a lot of ENTA gains or maybe never have a chance to get in because I’m waiting for some patient results that show the drug works.

EDP-235’s MoA—inhibiting the viral protease and thereby blocking viral replication—is well understood. That makes it hard to see why EDP-235 would not have efficacy in COVID patients, now that we know it can safely be dosed at levels that provide excellent plasma coverage. This is why ENTA is foregoing the usual phase-1b trial and proceeding directly to phase-2—or even a pivotal phase-2/3, if the FDA allows.